Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 12:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 5,494 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Active, not recruiting Phase 1 Interventional Results available

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

NCT03317405
View directory record Official record
Conditions
Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

NCT01188772
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-6987 for the Treatment of Mild to Moderate Asthma

NCT01296087
View directory record Official record
Conditions
Asthma
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 10, 2026, 12:49 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07601425
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions
ATV-1601, Placebo
Drug
Lead sponsor
Atavistik Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Augusta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

NCT04003389
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
142
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

NCT06269484
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 10, 2026, 12:49 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

NCT02153632
View directory record Official record
Conditions
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Interventions
amantadine HCl ER, Placebo
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 10, 2026, 12:49 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
24
States / cities
Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01957163
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, VI, UMEC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814
View directory record Official record
Conditions
Perimenopause, Menopause, Depression
Interventions
Estradiol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2 Interventional

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

NCT00570752
View directory record Official record
Conditions
Vascular Diseases
Interventions
Placebo, BMS-582949, Atorvastatin, Statin
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT01065935
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, Normal Saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

NCT03395184
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
57
States / cities
Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 3 Interventional

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

NCT01456325
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Erlotinib, Onartuzumab (MetMab), Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
56
States / cities
Chandler, Arizona • Hayward, California • Modesto, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

NCT01370317
View directory record Official record
Conditions
Asthma
Interventions
MK-1029, Placebo for MK-1029
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Costa Mesa, California • Rolling Hills Estates, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

NCT03215940
View directory record Official record
Conditions
Chronic Pain, Widespread
Interventions
Delta-9-Tetrahydrocannabinol, Cannabidiol, Placebos
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 10, 2026, 12:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.

NCT06075914
View directory record Official record
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Flavanols in Exercise and Aging

NCT01557738
View directory record Official record
Conditions
Aging
Interventions
High Flavanol Trial, Low Flavanol Trial, High Flavanol Trial; long-term, Low Flavanol Trial; long-term effects
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 10, 2026, 12:49 PM EDT
Terminated Phase 3 Interventional Results available

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT03028740
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
204
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 1 Interventional

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

NCT04597450
View directory record Official record
Conditions
PTSD
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

NCT03359785
View directory record Official record
Conditions
Schizophrenia
Interventions
Luvadaxistat, Matching Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 10, 2026, 12:49 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 10, 2026, 12:49 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplant
Interventions
Ixazomib Citrate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Little Rock, Arkansas • Rochester, Minnesota • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 10, 2026, 12:49 PM EDT